Codein Knoll

Quick links to important sections

Codein Knoll

Method of action: Antitussive Opioid

Treatment option: Cough

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Codein Knoll

Quick Facts

Property Description
Active ingredient Codeine (Methylmorphine)
Form Tablets (Oral preparation)
Pharmacological class Opioid analgesic / Opioid antitussive
General purpose Relief of moderate pain and non-productive cough
Origin Semi-synthetic alkaloid

Codein Knoll: Identity, Form, and Pharmacological Classification

Codein Knoll is a specific single-component drug presented as an oral preparation in the form of tablets. This medication is categorized pharmacologically as an opioid analgesic and an opioid antitussive, reflecting its potent central action on the nervous system. Codeine maintains a recognized role as an essential medicine for the treatment of adult patients. This classification is clinically recognized for its efficacy in providing foundational symptomatic relief. The standardized tablets facilitate precise, unit-dose delivery through the oral route of administration.

Composition and Origin of the Active Ingredient (Codeine)

The core therapeutic component is Codeine, formally known as Methylmorphine. Codeine is a semi-synthetic alkaloid, meaning it is chemically derived from the naturally occurring Opioid alkaloid, Morphine. In this specific formulation, Codeine is typically provided as the salt Codeine phosphate, along with necessary solid oral excipients for tablet creation. Codeine is a widely used opioid in the management of pain and cough, including its utility for addressing moderate acute pain following procedures.

General Therapeutic Purpose of Codeine's Dual Action

The general benefit of this preparation stems from the dual central action of Codeine. As an opioid analgesic, the drug modulates the central perception of moderate pain signals. Concurrently, its opioid antitussive property acts by directly influencing and depressing the cough center located in the brainstem. This combined mechanism allows Codein Knoll to provide effective symptomatic relief for both discomfort from pain and the severity of a persistent, non-productive cough.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH StatPearls

What side effects are possible with Codein Knoll?

Official Safety Profile and Adverse Reactions

Codeine's safety profile is documented by regulatory authorities, classifying possible effects by frequency and the body system affected. These classifications are used to communicate the risk associated with the medicine.

Adverse reactions classified as common in official labeling include effects related to the Nervous System, such as drowsiness, light-headedness, dizziness, and sedation. Common effects on the Gastrointestinal System include nausea, vomiting, and constipation. Less common reactions may include confusion, itching, and seizures.


Serious Adverse Reactions and Key Regulatory Constraints

The regulatory profile highlights specific serious and potentially life-threatening risks. The most critical is the risk of Life-Threatening Respiratory Depression, particularly when treatment is initiated or the dose is increased. Official labeling also documents the inherent risks of opioid addiction, abuse, and misuse.

Specific safety constraints are placed on certain patient groups. Codeine is contraindicated for any use in children under 12 years of age and in individuals known to be ultra-rapid metabolizers of the active ingredient. Use during pregnancy and in breastfeeding women is generally not recommended due to the risk of exposing the infant to high levels of the active metabolite. Furthermore, patients with pre-existing conditions like significant respiratory depression or known gastrointestinal obstruction are also subject to safety constraints outlined in the prescribing information.

Prolonged use of the medication may lead to the development of physical dependence and tolerance, a pattern documented in official sources. These mandated classifications establish the overall framework for understanding the medicine's risk profile.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Codeine is officially classified as a severe and potentially life-threatening event requiring immediate medical intervention. The documented clinical manifestations are centered on acute Central Nervous System (CNS) and respiratory depression.

Documented Signs and Severe Outcomes

Overdose may present with profound sedation, excessive sleepiness, confusion, and difficulty breathing. Physiological signs include slow or shallow breathing, apnea (no breathing), bluish discoloration of the lips and skin (cyanosis), cold/clammy skin, pinpoint pupils (miosis), and low blood pressure (hypotension). The severe, life-threatening outcomes documented in regulatory warnings are coma, shock, and death, primarily due to respiratory failure.

When to Seek Urgent Help

Immediate medical attention must be sought for any suspected overdose or accidental ingestion, as the consumption of even a single dose can be fatal, especially in children. Regulatory guidance mandates that emergency services (such as 911) or a Poison Control Center be contacted without delay upon observing signs of profound sedation or respiratory compromise.

Reversal and Risk Factors

The specified emergency treatment includes the administration of Naloxone, an opioid antagonist used to reverse the depressive effects. Official warnings highlight increased risk among specific populations, including ultra-rapid CYP2D6 metabolizers, pediatric patients under 12 years of age, and patients with pre-existing chronic pulmonary disease.

Therapeutic Uses of Codein Knoll

The medication is used to provide supportive symptomatic relief for both pain and cough. This therapeutic scope is relevant in two main areas where the medication assists in managing acute, distressing symptoms.


Dual Therapeutic Focus: Symptom Management

The primary therapeutic use of this preparation is the symptomatic management of moderate intensity pain and the suppression of a persistent, non-productive cough. It is commonly applied in scenarios that require supportive symptom management, especially in contexts such as following minor surgical or dental procedures, or during episodes of disruptive, dry coughing after respiratory infections. The medication contributes to easing the overall symptom load and supports general well-being during symptomatic periods. This role in symptom control is intended to provide support during difficult acute episodes.

“The medication is often applied when symptoms create noticeable physiological strain and when supportive symptom management is appropriate.”

Quick Fact: Relief for Pain and Cough
Symptom Axis: Physical Discomfort / Heightened Physiological Activity
Clinical Context: Acute episodes of moderate pain or persistent, non-productive cough
Patient Benefit: Contributes to easing the overall symptom load and assists with maintaining functional stability

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Codein Knoll — Official Regulatory Information

The official eligibility profile for Codein Knoll is strictly defined by national and international health authorities. The standard approved population is generally Adults (18 years and older) for whom no specific contraindications are documented.

Absolute Contraindications (Must Not Use)

Codein Knoll is contraindicated in several groups due to documented, non-negotiable risks. This absolute exclusion applies to all children younger than 12 years of age for any indication. It is also contraindicated in adolescents under 18 following tonsillectomy or adenoidectomy surgery, and in any patient known to be a CYP2D6 ultra-rapid metabolizer. Furthermore, the medicine is prohibited for women who are breastfeeding and for individuals with significant respiratory depression, acute or severe bronchial asthma, or known paralytic ileus.

Restricted and Conditional Use

Eligibility is limited for specific patient categories where use requires caution or is not recommended. The label advises against use in adolescents (12–18 years) with compromised respiratory function. Use is restricted in elderly patients and those with hepatic or renal impairment, often necessitating careful monitoring. Prolonged maternal use during pregnancy carries the documented risk of Neonatal Opioid Withdrawal Syndrome.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Codeine's interaction profile is established in official regulatory documents based on two main categories: combined central nervous system effects and changes in drug exposure.

Interaction Type Interacting Substances/Classes
Central Nervous System (CNS) Depressants Benzodiazepines, other opioids, tranquilizers, muscle relaxants, and alcohol.
Enzyme System Modifiers CYP2D6 Inhibitors, CYP3A4 Inhibitors, and CYP3A4 Inducers.
Other Pharmacodynamic Agents Monoamine Oxidase Inhibitors (MAOIs) and Serotonergic drugs.

Co-administration with CNS Depressants is documented to increase the risk of profound sedation, severe respiratory depression, coma, and death. Alcohol is included in this restriction as it also depresses the CNS. The use of Monoamine Oxidase Inhibitors (MAOIs) is restricted concurrently and for 14 days after their use has stopped due to the risk of potentiating effects like respiratory depression.

Official labeling also addresses pharmacokinetic alterations involving the Cytochrome P450 (CYP) enzyme system. Concomitant use with CYP2D6 Inhibitors can decrease the concentration of codeine’s active metabolite, which may result in reduced clinical effect. Conversely, CYP3A4 Inhibitors or the discontinuation of a CYP3A4 Inducer may require monitoring due to altered codeine plasma levels. Additionally, Serotonergic drugs may increase the risk of serotonin syndrome.

Specific restrictions include avoiding combination with mixed agonist/antagonist or partial agonist opioid analgesics, such as pentazocine or buprenorphine.

Mechanism of Action

Codein Knoll functions as a prodrug, an inactive compound that undergoes biochemical transformation upon systemic absorption. The primary metabolic step involves O-demethylation in the liver, a process catalyzed by the polymorphic cytochrome P450 enzyme CYP2D6, which converts a small fraction of codeine into the active metabolite, morphine.

This morphine metabolite acts as an agonist at central nervous system mu-opioid receptors (MOR). Activation of these G-protein coupled receptors initiates an intracellular signaling cascade. This leads to the hyperpolarization of neurons through increased potassium conductance and inhibition of adenylate cyclase, resulting in a decrease in intracellular cyclic adenosine monophosphate (cAMP) and reduced calcium influx.

The resulting system-level physiological consequence of MOR activation in ascending nociceptive pathways is the inhibition of presynaptic neurotransmitter release, functionally reducing the transmission of discomfort-related signals between the brain and spinal cord. Furthermore, codeine itself, and the metabolite codeine-6-glucuronide, also interact directly with MORs to modulate activity, including a separate central action in the medulla oblongata that modifies the reflex arc controlling cough.

Dosage and Administration Information

The administration of Codein Knoll is strictly by the oral route using immediate-release tablet formulations. A core principle guiding its use is the utilization of the lowest effective dosage for the shortest possible duration.

Standardized Adult Dosing

For pain management, the typical adult single dose of the codeine component ranges from 15 mg to 60 mg. This single dose may be repeated every four hours as needed. Single doses exceeding 60 mg generally fail to provide commensurate pain relief and increase the likelihood of adverse events. The established maximum cumulative dose should not exceed 360 mg within a 24-hour period.

The medication is generally prescribed for short-term symptomatic relief. For acute, non-cancer pain, the duration of continuous use is typically limited to a maximum of three days without medical re-evaluation. Administration of the tablets may occur with or without food.

Population-Specific Use Restrictions

Specific parameters exist regarding age and physiological impairment for this medication. Codeine is contraindicated for use in children younger than 12 years of age. Furthermore, dose adjustments, typically in the form of a reduction, are necessary for older adults and patients with known hepatic or renal impairment due to altered drug clearance.

Recent Clinical Evidence

Codein Knoll: Recent Clinical Evidence


Evidence for Use in Acute Moderate Pain Relief

Research examining the use of Codein Knoll has primarily centered on exploring changes in discomfort and outcomes related to physical discomfort in adults experiencing acute pain following surgical or dental procedures. These evaluations used rigorous, short-term, single-dose Randomized Controlled Trials (RCTs), and their findings were combined in Systematic Reviews and Meta-analyses. Research describes patterns observed in these studies, which included monitoring the proportion of patients who reported a minimum level of change in discomfort within a few hours. Evidence for the single-agent form of codeine is characterized by reviews of the pooled data as Moderate. Findings indicate that studies involving codeine in a fixed-dose combination are characterized by a Higher level of evidence grading for short-term pain relief outcomes.


Evidence for Use in Suppression of Non-Productive Cough

The antitussive property of Codein Knoll was evaluated in research scenarios exploring periods of increased symptom activity in adults. These studies monitored outcomes related to cough frequency or intensity. When studies explored short-term symptom changes, evidence consistency was low. Official regulatory assessments describe that trials did not consistently report outcomes that suggested a clear distinction from control groups for cough suppression. Based on systematic reviews, the evidence for this use is often characterized as having low certainty.


Research Limitations and Evidence Gaps

A key uncertainty lies in the low evidence quality and variability of findings reported for the cough-suppression indication. For both approved uses, the follow-up durations were limited, focusing on acute periods rather than long-term use. The existing data do not provide information about chronic use, and long-term effects are not fully established. Furthermore, data for pediatric populations (children under 12 years) remain insufficient in the core evidence base, leading to regulatory restrictions and highlighting the need for caution regarding use in special populations.

Key Studies & References

  1. WHO Model List of Essential Medicines (Core Listing)
  2. Codeine - StatPearls - NCBI Bookshelf (General Pharmacological Context)

Frequently Asked Questions (FAQ)

Common questions about Codein Knoll (FAQ)

Q: Do you get Codein Knoll over the counter or do you need a prescription?

A: According to official regulatory classifications, this medication is typically classified as a controlled substance, such as Schedule II in the United States. This classification means that the drug requires a prescription from a healthcare provider for dispensing.

Q: Is Codein Knoll used for both short-term and chronic conditions?

A: Official regulatory documents emphasize that Codein Knoll is generally intended for short-term symptomatic relief. Prescribing instructions typically highlight the importance of using the lowest effective dosage for the shortest possible duration.

Q: What are the official warnings related to taking Codein Knoll with alcohol?

A: Official warnings document that taking Codein Knoll with alcohol significantly increases the risk of severe side effects, including profound sedation, respiratory depression (slowed or ineffective breathing), coma, and death. This is due to the additive depressant effects both substances have on the central nervous system.

Q: Can I take Codein Knoll if I have a history of breathing problems?

A: The medication is contraindicated (restricted from use) for individuals with conditions like severe bronchial asthma or existing significant respiratory depression. Regulatory documents advise that caution or dose adjustment may be necessary for patients with other compromised breathing functions, such as sleep apnea.

Q: Is Codein Knoll associated with any withdrawal symptoms when stopped?

A: Official patient information states that prolonged use of this medication may lead to physical dependence. If the medication is stopped abruptly after dependence has developed, symptoms of drug withdrawal syndrome may occur.

Q: What is the main difference between Codein Knoll and other common pain relievers?

A: Codein Knoll is classified as an opioid analgesic, which means it works primarily by acting on mu-opioid receptors in the central nervous system. This pharmacological mechanism of action is what differentiates it from many common non-opioid pain relievers.

Q: Can Codein Knoll be taken with simple vitamins or supplements?

A: Regulatory information provides detailed warnings for interactions with specific drug classes, but the safety of combining the medication with all simple vitamins or supplements is not established in the same standardized way as prescription medicines. Official documents advise that patients should seek information from a healthcare provider regarding all non-prescription products, including vitamins and supplements.

Q: Why is Codein Knoll sometimes combined with other active ingredients?

A: Research examining fixed-dose combination products containing codeine has indicated a Higher level of evidence grading for positive outcomes related to short-term pain relief. This suggests that the combined use of codeine with other active ingredients may result in different clinical characteristics in studies.

Q: Are there any specific foods or drinks to avoid while taking Codein Knoll?

A: The administration of Codein Knoll tablets may occur with or without food. However, official labeling strongly cautions against combining the medication with alcohol, as this can lead to severely increased risks, including respiratory depression and profound sedation.

Q: Does Codein Knoll cause dependency or addiction in all people who take it?

A: Official regulatory documents document the inherent risk of opioid addiction, abuse, and misuse associated with this substance. The risk is an established property of the drug class itself, particularly with prolonged use, though it is not stated to affect all individuals who take it.

Q: Is Codein Knoll appropriate for older adults?

A: Use in elderly patients is considered restricted and conditional by regulatory bodies. Due to factors like altered drug clearance, older adults may require careful monitoring and often necessitate a dose adjustment, typically a reduction, to minimize the risk of adverse events.

Q: Does Codein Knoll affect the ability to drive or operate machinery?

A: Official warnings advise against engaging in hazardous tasks requiring full mental alertness, such as driving or operating heavy machinery. This caution is due to common adverse reactions documented in official labeling, including drowsiness, dizziness, and sedation.

Q: Is it true that Codein Knoll is less effective for some people?

A: Yes, official regulatory data recognizes that individuals who are poor metabolizers of codeine may experience a reduced or absent analgesic effect. This difference is due to variations in the liver enzyme CYP2D6, which is responsible for converting codeine into its active form, morphine.

Q: What type of pain relief does Codein Knoll provide?

A: Regulatory documents indicate that the medication is primarily indicated for the relief of mild to moderately severe pain. It functions as an opioid analgesic, working to modulate the central nervous system's perception of pain signals.

Q: Why do some people feel dizzy when they stand up after taking Codein Knoll?

A: Official patient information notes that adverse effects can include dizziness or lightheadedness, particularly when a person changes position quickly, such as standing up from sitting or lying down. This is an effect that is often noted when treatment with the medication is first initiated.

Q: Does research show any long-term safety concerns with Codein Knoll?

A: Research evidence documents that the follow-up periods in studies have been limited to acute use, meaning the long-term effects are not fully established. However, published research has associated prolonged use of codeine with risks that include the development of dependence and reports of depressive symptoms.

Q: Are there different forms of Codein Knoll (e.g., tablet, liquid)?

A: The specific product, Codein Knoll, is defined in official documents as a tablet intended for administration via the oral route.

Q: What is the risk of Codein Knoll interacting with herbal products like St. John's Wort?

A: Official patient information indicates that herbal products, such as St. John's Wort, may interact with codeine. Because these interactions are a documented risk, it is important to communicate all herbal products being used to a healthcare provider.

Q: If Codein Knoll doesn't work for me, what does that mean?

A: Regulatory annotations indicate that one reason for reduced effect can be if a patient is a poor metabolizer of codeine. This means that the body is less efficient at converting codeine into its primary active pain-relieving metabolite, morphine, which can result in reduced or no analgesic effect.

Q: What is the most serious, but rare, side effect linked to Codein Knoll?

A: The most critical risk documented in official safety profiles is the risk of Life-Threatening Respiratory Depression (dangerously slow or shallow breathing). While serious adverse reactions are documented, the official information notes that in severe cases, these effects may be life-threatening and very rarely fatal.

Q: Is it possible to develop a tolerance to the effects of Codein Knoll?

A: Official regulatory documents state that prolonged use of this medication may lead to the development of tolerance. Tolerance is a pattern where an increasing dosage may be required to achieve the same initial effect, and its development is often associated with physical dependence.

Q: What kinds of surgical pain is Codein Knoll typically used to manage?

A: Research evidence themes regarding the use of Codein Knoll primarily focus on the relief of acute pain. Studies that have examined the effectiveness of the drug have largely centered on pain experienced following surgical or dental procedures.

Q: Are there any contraindications related to mental health conditions and Codein Knoll?

A: Official documents recommend caution or special monitoring for patients with a history of certain mental health disorders, such as major depression, or a history of substance misuse disorder. Specific contraindications also exist for concurrent use with medications like MAOIs (Monoamine Oxidase Inhibitors), which are used to treat some mental health conditions.

Q: Can I take Codein Knoll if I am already taking an antidepressant?

A: Official labeling documents known interactions with Serotonergic drugs and specific classes of antidepressants, such as MAOIs and tricyclic antidepressants. These interactions carry the risk of increased sedation and other serious effects, and full disclosure of all current medications to a healthcare provider is noted as important in official documentation.

Q: What does the research say about Codein Knoll and long-term use?

A: Research documents confirm that the follow-up durations for studies are limited to acute periods, and the existing evidence base does not provide information about chronic use. Therefore, the long-term effects of the medication are not fully established in official regulatory documents.

Q: Why is Codein Knoll often mentioned in discussions about pain management?

A: Codein Knoll maintains clinical recognition due to its established role as an opioid analgesic for managing moderate acute pain. Its inclusion on the World Health Organization (WHO) Model List of Essential Medicines further highlights its global utility in foundational symptomatic relief.

Q: Can taking Codein Knoll affect my mood?

A: Official adverse reactions include various effects on the Nervous System, such as drowsiness and confusion. Furthermore, published research has noted an association between prolonged codeine use and the potential for depressive symptoms.

Q: Do regulatory bodies classify Codein Knoll as high-risk or low-risk?

A: Regulatory bodies assign Codein Knoll the classification of a Schedule II controlled substance, and it carries a Boxed Warning for critical risks like life-threatening respiratory depression. This strict classification indicates that regulatory bodies consider the drug to have significant risks requiring careful control and monitoring.

Q: Is it mandatory to speak to a doctor before restarting Codein Knoll after a break?

A: Due to the classification of the drug as a controlled substance, and the regulatory principle of using the lowest effective dosage for the shortest possible duration, professional guidance is generally necessary. A healthcare provider’s assessment can help determine the appropriate course before restarting the medication after a break.

How should Codein Knoll be stored and disposed of?

Official Storage and Disposal Requirements

Codeine Knoll tablets must be stored according to regulatory guidelines to maintain drug stability and prevent misuse.

Storage Requirement Official Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C), away from excess heat.
Container Keep in the original container, tightly closed, and away from moisture.
Child Safety Store out of the sight and reach of children in a secure, often locked, location due to the risk of fatal accidental ingestion.

Disposal Instructions:

Unused or expired product should be disposed of immediately via a DEA-authorized drug take-back program. If a take-back option is not readily available, the FDA specifies that opioids like Codeine must be immediately flushed down the toilet to prevent dangerous accidental exposure, which outweighs potential environmental concerns for this specific drug class. Do not place unused medicine in household trash unless otherwise instructed by a local program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Codein Knoll found in:

A-Z Index: